文献速递造血干细胞移植与细胞治疗白血病

基于SECTM1的CAR T细胞中富集CD7低表达/阴性亚群对CD7阳性恶性肿瘤显示疗效

SECTM1-based CAR T cells enriched with CD7-low/negative subsets exhibit efficacy in CD7-positive malignancies.
PubMed 文献 · Blood Adv · 2023-01-01

研究利用SECTM1的胞外域作为识别域构建靶向CD7的CAR T细胞。体外实验中,SECTM1 CAR T细胞杀伤多数高表达CD7的T细胞,而CD7低表达或阴性的SECTM1 CAR T细胞可存活、扩增,并对CD7阳性恶性细胞系及T-ALL和AML患者原代白血病原始细胞显示强细胞毒性,体内实验也显示抑制异种移植瘤生长的效果。对CD7阳性恶性肿瘤患者的临床疗效潜力仍需更多探索。

要点

  • SECTM1 CAR T细胞在体外杀伤多数高表达CD7的T细胞。
  • CD7低表达或阴性的SECTM1 CAR T细胞可存活、扩增,并对CD7阳性恶性细胞系及T-ALL和AML患者原代白血病原始细胞显示强细胞毒性。
  • SECTM1 CAR T细胞在体内显示抑制异种移植瘤生长的效果。

核心结论

  • 基于SECTM1的CAR T细胞富集CD7低表达/阴性亚群,在体外和体内对CD7阳性恶性肿瘤显示疗效,对CD7阳性恶性肿瘤患者的临床疗效潜力仍需更多探索。

研究设计与样本

  • 利用SECTM1的胞外域作为识别域构建靶向CD7的CAR T细胞,并进行体外和体内功能验证。

主要发现

  • SECTM1 CAR T细胞在体外杀伤多数高表达CD7的T细胞。
  • CD7低表达或阴性的SECTM1 CAR T细胞可存活、扩增,并对CD7阳性恶性细胞系及T-ALL和AML患者原代白血病原始细胞显示强细胞毒性。
  • SECTM1 CAR T细胞在体内显示抑制异种移植瘤生长的效果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 对CD7阳性恶性肿瘤患者的临床疗效潜力仍需更多探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD7 has been found to be a promising chimeric antigen receptor (CAR) T cell target in several clinical trials. However, its expression on normal T cells poses additional challenges in CD7-directed CAR therapy, such as complete fratricide, contamination with malignant cells, and immune suppression due to T-cell aplasia. By taking advantage of evolved affinity between ligand and receptor, we constructed a CD7-directed CAR with the extracellular domain of SECTM1, a natural ligand of CD7, as the recognition domain. SECTM1 CAR T cells killed the majority of T cells with high CD7 expression in vitro. However, SECTM1 CAR T cells with low or negative CD7 expression survived, expanded, and showed strong cytotoxicity to CD7+ malignant cell lines and primary leukemic blasts from patients with T-cell acute lymphoblastic leukemia and acute myelogenous leukemia in vitro. It also exhibited efficacy in inhibiting xenograft tumor growth in vivo. More exploration is needed for clinical efficacy potential to patients with CD7+ malignancies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Wei W, Ma H, Yang D, et al. SECTM1-based CAR T cells enriched with CD7-low/negative subsets exhibit efficacy in CD7-positive malignancies. Blood Adv. 2023. PMID: 36848638. doi:10.1182/bloodadvances.2022008402

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。